LC
VIR icon

Lindbrook Capital’s Vir Biotechnology VIR Stock Holding History

Lindbrook Capital’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$2.57K Hold
396
– – ﹤0.01% 2206
2024
Q4 		$2.91K Buy
396
+200
+102% +$1.58K ﹤0.01% 2190
2024
Q3 		$1.47K Sell
196
-1,357
-87% -$11.8K ﹤0.01% 2422
2024
Q2 		$13.8K Buy
1,553
+98
+7% +$940 ﹤0.01% 1452
2024
Q1 		$14.7K Buy
1,455
+214
+17% +$2.18K ﹤0.01% 1368
2023
Q4 		$12.5K Buy
1,241
+813
+190% +$7.43K ﹤0.01% 1423
2023
Q3 		$4.01K Buy
428
+417
+3,791% +$5.95K ﹤0.01% 1858
2023
Q2 		$270 Hold
11
– – ﹤0.01% 2633
2023
Q1 		$256 Sell
11
-63
-85% -$1.61K ﹤0.01% 2689
2022
Q4 		$1.87K Sell
74
-169
-70% -$4.14K ﹤0.01% 2258
2022
Q3 		$5K Buy
243
+139
+134% +$3.53K ﹤0.01% 1698
2022
Q2 		$3K Buy
104
+88
+550% +$2.05K ﹤0.01% 1855
2022
Q1 		$0 Sell
16
-8
-33% -$237 ﹤0.01% 2623
2021
Q4 		$1K Buy
+24
New +$940 ﹤0.01% 2012

Other funds holding VIR

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's VIR Position: Q1 2025 in Review

Lindbrook Capital held its Vir Biotechnology (VIR) position steady in Q1 2025 at 396 shares worth $2.57K. The position accounts for ﹤0.01% of the portfolio, ranked #2206.

Lindbrook Capital first reported a position in VIR in Q4 2021 and has held it in 14 quarters since. The position peaked at $14.7K in Q1 2024. 233 funds tracked by Wall St. Rank hold VIR as of Q1 2025.

  • Lindbrook Capital held 396 shares of Vir Biotechnology worth $2.57K as of Q1 2025.
  • Lindbrook Capital left its Vir Biotechnology share count unchanged in Q1 2025.
  • Vir Biotechnology made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2206 holding.
  • Lindbrook Capital first reported a position in Vir Biotechnology in Q4 2021 and has held it in 14 quarters since.
  • Lindbrook Capital's Vir Biotechnology position peaked at $14.7K in Q1 2024.
  • 233 funds tracked by Wall St. Rank held Vir Biotechnology as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.